Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week high Wednesday as it is currently trading at $43, above its previous 52-week high of $42.97 with 791,943 shares traded as of 10:50 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.
Omnicare has a market cap of $4.32 billion and is part of the services sector and wholesale industry. Shares are up 16.3% year to date as of the close of trading on Tuesday.
Omnicare, Inc. operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States and Canada. The company operates in two segments, Long-Term Care Group and Specialty Care Group. The company has a P/E ratio of 23.8, above the S&P 500 P/E ratio of 17.7.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Omnicare as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full
52-week high stocks
or get investment ideas from our
Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE